MPM kicks off a new I/O play­er with $44.5M round and a new un­der­stand­ing of the T cell re­cep­tor

Af­ter run­ning in stealth mode for more than a year gain­ing bet­ter un­der­stand­ing of the com­plex struc­ture of sub­units in­volved in the T cell re­cep­tor, TCR² has now jumped in­to view in Cam­bridge, MA with a $44.5 mil­lion start­up round and some big plans to make some orig­i­nal progress in im­muno-on­col­o­gy.

Gar­ry Men­zel, the for­mer COO at Reg­u­lus, has tak­en charge as the new CEO. He’s team­ing up with ex-Mer­ck KGaA sci­en­tist Robert Hofmeis­ter, who’s cred­it­ed with a se­nior role in de­vel­op­ing that com­pa­ny’s PD-L1 check­point, and Patrick Baeuer­le, the for­mer CSO at Mi­cromet.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER